Introduction Dabrafenib and trametinib are oral targeted agents indicated for BRAF mutated non-small cell lung cancer and melanoma. There is little data to support the administration of these two agents via enteral feeding tube. This case series describes three patients who received compounded dabrafenib and trametinib suspensions through enteral feeding tubes. Case report: We present three patients who required dabrafenib and trametinib to be prepared as a non-standard compound for the medications to be administered via feeding tube. The patients were diagnosed with with BRAF mutated cancers including melanoma, non-small-cell lung carcinoma, and anaplastic thyroid cancer. In all three cases, there was evidence of initial disease response on imaging, and there were no unexpected toxicities secondary to dabrafenib and trametinib. Discussion: There are patients that are unable to tolerate medications by mouth due to dysphagia, anatomical malfunctions, or other digestive disorders. There is limited literature that describes preparation of trametinib and dabrafenib into an enteral suspension. Identifying a safe and efficacious method of administering these two medications via feeding tube ensures that these patients continue to be able to receive them as part of their anti-cancer therapy. Conclusion: Despite the lack of available data, compounding of dabrafenib and trametinib may be clinically appropriate when benefits outweigh the risk of unconventional administration. Further studies are warranted to assess for the pharmacokinetics, pharmacodynamics, stability, and storage for these liquid medications.

15544 Background: We performed a retrospective investigation of the combined induction chemotherapy and radiotherapy for advanced nasopharyngeal carcinomas at Cancer Center-Ho Chi Minh City-Vietnam. Method: In the period 1998–2000, the treatment regimen induced 2 or 3 cycles of cisplatin and 5-Fluorouracile followed by radiation. Cisplatin was given in the dose of 100 mg/m2/day 1 and 5FU 1,000 mg/m2/d1–4. Radiotherapy included 2 lateral cervical portals and an anterior cervical portal with Cobalt 60. Results: One hundred sixteen patients (92 men and 24 women) with age ranging from 15 to 72 years were enrolled. The overall response rate to induction chemotherapy was 66% (15% complete responses (CRs) and 51% partial responses (PRs)). After combined treatment, overall response rates was 92% (82% CRs, 10% PRs). Toxicities in the chemotherapy were mainly myelosuppression (40%), nausea/vomiting (27%), mucositis (28%), and diarrhea (12%). There was 9 recurrences (2 local, 7 distant), 7 deaths and 1 refusal of radiotherapy. Conclusion: The immediate local response rates was rather high despite of the common of major myelotoxicities and expensive cost. The long-term survival benefit need to be reevaluated carefully later. No significant financial relationships to disclose.